Table 2.
Patient Demographics: Clinical Features at Study Entry
| Demographic Factor | Group A (n = 14) |
Group B (n = 20) |
Overall (n = 34) |
|---|---|---|---|
| Age (years) | |||
| Mean | 36 | 40 | 39 |
| Median | 32 | 46 | 43 |
| Range | 17–52 | 8–65 | 8–65 |
| Gender | |||
| Male | 8 | 12 | 20 |
| Female | 6 | 8 | 14 |
| Diagnosis | |||
| AML/MDS/MF | 6 | 10 | 16 |
| ALL | 2 | 1 | 3 |
| CML | 1 | 4 | 5 |
| NHL/CLL | 3 | 3 | 6 |
| Myeloma | 1 | 1 | 2 |
| Nonmalignant | 1 | 1 | 2 |
| HLA match | |||
| HLA matched | 13 | 18 | 31 |
| Mismatch | 1 | 2 | 3 |
| Cell source | |||
| PSC | 8 | 17 | 25 |
| Marrow | 6 | 3 | 9 |
| Donor type | |||
| MRD | 8 | 14 | 22 |
| URD | 6 | 6 | 12 |
| Chronic GVHD present | |||
| Yes | 14 | 20 | 34 |
| No | 0 | 0 | 0 |
| Corticosteroidsa | |||
| At study entry | 14 | 14 | 28 |
| Median dose (mg/kg/day) | 0.4 | 0.2 | 0.3 |
| Lung injury pattern | |||
| Restrictive | 3 | 6 | 9 |
| Obstructive | 11 | 14 | 25 |
| NIH Lung Function Score (LFS)b | |||
| Median | 7 | 8 | 7.5 |
| Mean | 8 | 8 | 8 |
| Range | 2–11 | 4–12 | 2–12 |
| Supplemental O2 required | 1 | 2 | 3 |
AML indicates acute myelogenous leukemia; MDS, myelodysplasia; MF, myelofibrosis; CML, chronic myelogenous leukemia; NHL, non-Hodgkin lymphoma; ALL, acute lymphoblastic leukemia.
a
Median equivalent dose of prednisone.
b
LFS was determined for subjects with obstructive lung disease only.